Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

Completed

Conditions studied: Dry Eye Disease

In brief

The objective of this retrospective chart review is to evaluate the patient characteristics, treatment variations and efficacy of a second trial of Cyclosporine Ophthalmic Emulsion 0.05% therapy in chronic dry eye patients who were initially treated with Cyclosporine Ophthalmic Emulsion 0.05% but discontinued use after less than 12 weeks of treatment.

Key facts

Study ID

NCT00827255

Run by

Allergan

People needed

35

Starts

2009-01-01

Expected to finish

2009-10-01

Last updated by the study team

2019-04-25

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults >16 years of age
• Dry eye patients
• Subject with history of less than 12 weeks of initial RESTASIS® treatment
• Subject started second trial of RESTASIS® treatment prior to June 1, 2008
• First day of second trial of RESTASIS® started ≥ 4 weeks after the last day of previous RESTASIS® treatment

You may not qualify if…

• Patients with Contact Lens Intolerance
• Patients with Ocular Rosacea

Where it is running

• Study site — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.